NEW YORK – Infectious disease firm Karius announced Thursday that it has raised $100 million in a Series C financing round with new and existing investors.

纽约——传染病公司Karius周四宣布，它已与新的和现有的投资者在C轮融资中筹集了一亿美元。

The funding round was co-led by Khosla Ventures and new investors 5AM Ventures and Gilde Healthcare, Karius said in a statement. Other investors include new investor Seventure Partners and existing investors Softbank Vision Fund 2, General Catalyst, HBM Healthcare Investments, Blue Water Life Sciences, Innovation Endeavors, and Waycross Ventures, among others. .

卡里乌斯在一份声明中表示，这轮融资由科斯拉风险投资公司、新投资者5AM风险投资公司和吉尔德医疗集团共同牵头。其他投资者包括新投资者Seventure Partners和现有投资者Softbank Vision Fund 2、General Catalyst、HBM Healthcare Investments、Blue Water Life Sciences、Innovation Effirations和Waycross Ventures等。。

The funding will be used to broaden the reach of the company's Karius Test for infectious diseases that uses genomic analysis and artificial intelligence to detect over 1,000 pathogens from a blood sample. The investment will allow the Redwood City, California-based firm to expand access to the test beyond the hospital setting, it noted. .

这笔资金将用于扩大该公司的Karius传染病检测范围，该检测使用基因组分析和人工智能从血液样本中检测出1000多种病原体。它指出，这项投资将使这家总部位于加利福尼亚州红木市的公司能够将检测范围扩大到医院以外。。

The funding will also be used to 'support research into the broader health implications of Karius' microbial cell-free DNA technology beyond infectious diseases,' the company added.

该公司补充说，这笔资金还将用于“支持对卡里乌斯‘微生物无细胞DNA技术’超越传染病的更广泛健康影响的研究”。

The investment 'will significantly enhance our capacity to deliver rapid diagnostic testing to more patients, where faster treatment saves more lives and significant healthcare resources,' Karius CEO Alec Ford said in a statement.

Karius首席执行官亚历克·福特（AlecFord）在一份声明中说，这项投资将大大提高我们为更多患者提供快速诊断检测的能力，更快的治疗可以挽救更多的生命和大量的医疗资源。

The firm also announced that three new members would join its board of directors: Alex Morgan, partner at Khosla Ventures, Joep Muijrers, general partner at Gilde Healthcare, and Andrew Booth, venture adviser to 5AM Ventures and CFO of AbCellera Biologics.

该公司还宣布将有三名新成员加入董事会：科斯拉风险投资公司合伙人亚历克斯·摩根、吉尔德医疗保健公司普通合伙人乔普·穆雷尔斯和5AM风险投资公司风险顾问兼AbCellera Biologics首席财务官安德鲁·布斯。

In 2020, Karius raised $165 million in a series B financing round.

2020年，卡里斯在B轮融资中筹集了1.65亿美元。